缬沙坦联合百令胶囊对早期糖尿病肾病患者尿白蛋白排泄率的影响观察

目的：观察缬沙坦联合百令胶囊对早期糖尿病肾病（DN）患者尿白蛋白排泄率（UAER）水平的影响,探讨其对早期DN的保护作用。方法：60例早期DN患者随机分为缬沙坦组（n=30）和联合治疗组（n=30）,在控制饮食、调控血糖基础上,缬沙坦组给予缬沙坦160 mg,qd治疗;联合治疗组再缬沙坦组基础上再加用百令胶囊2.0 g,po,tid。两组疗程12周。比较两组患者治疗前后UAER、平均动脉压（MAP）、血清肌酐（Scr）及糖化血红蛋白（HbA1c）水平变化。结果：治疗后联合治疗组和缬沙坦组UAER均较治疗前显著下降（P〈0.01）,且联合治疗组UAER下降更明显（P〈0.01）;两组治疗后MAP较治疗前均明显下降（P〈0.01）,但治疗后两组间比较差异无统计学意义（P〉0.05）。两组Scr和HbA1c治疗前后比较,差异均无统计学意义（P〉0.05）。结论：缬沙坦联合百令胶囊治疗早期DN疗效确切,可有效减轻DN患者微量白蛋白尿。

Observation on the Influence of Valsartan Combined with Bailing Capsules on Urinary Albumin Excretion Rate in Early Stage of Type 2 Diabetic Nephropathy

ABSTRACT Objective: To observe the influence of valsartan combined with Bailing capsules on urinary albumin excretion rate in early stage of type 2 diabetic nephropathy (DN), and explore its protection in early DN. Methods:Sixty patients with early DN were randomly divided into two groups. On the basis of diet control and blood glucose regulation, the control group (n=30) was given valsartan 160 mg, qd, while the prevention group (n=30) was treated by valsartan (160 mg·d^-1) combined with Bailing capsules (2.0g,po,tid), and the treatment course was 12 weeks. The urinary albumin excretion rate (UAER), mean arterial blood pressure (MAP), serum creatinine (Scr) and hemoglobin A1c (HbA1c) were measured and compared before and after the treatment in the two groups.Results:UAER in the two groups was significantly reduced after the treatment compared with that before the treatment (P<0.01), and that in the prevention group was obviously lower than that in the control group (P<0.01). MAP in the two groups was significantly decreased after the treatment as well (P<0.01), while there was no significant difference between the two groups. Scr and Hb Alc in the two groups showed no significant changes before and after the treatment (P>0.05). Conclusion:Valsartan combined with Bailing capsules shows certain effects in the treatment of early stage of type 2 diabetic nephropathy by decreasing the urinary albumin excretion.